Evidence map›Paper›PMID 38933087›Full record

ArticleJournal of molecular and cellular cardiology plus2024

Treatment with αvβ3-integrin-specific 29P attenuates pressure-overload induced cardiac remodelling after transverse aortic constriction in mice.

Alexandra Njegić, Lina Laid, Min Zi, Eleni Maniati, Jun Wang, Alexandru Chelu, Laura Wisniewski, Jenna Hunter, Sukhpal Prehar, Nicholas Stafford and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular and cellular cardiology plus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Alexandra NjegićBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom.
Lina LaidDivision of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester M13 9PT, United Kingdom.
Min ZiDivision of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester M13 9PT, United Kingdom.
Eleni ManiatiBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom.
Jun WangBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom.
Alexandru CheluDivision of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester M13 9PT, United Kingdom.
Laura WisniewskiBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom.
Jenna HunterDivision of Diabetes, Endocrinology & Gastroenterology, School of Medical Sciences, University of Manchester, Manchester M13 9PT, United Kingdom.
Sukhpal PreharDivision of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester M13 9PT, United Kingdom.
Nicholas StaffordDivision of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester M13 9PT, United Kingdom.
Chaim GilonInstitute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
Amnon HoffmanInstitute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, P.O. Box 12065, Jerusalem 91120, Israel.
Michael WeinmüllerInstitute for Advanced Study, TUM School of Natural Science, Technische Universität München, Lichtenbergstr. 4, 85747 Garching, Germany.
Horst KesslerInstitute for Advanced Study, TUM School of Natural Science, Technische Universität München, Lichtenbergstr. 4, 85747 Garching, Germany.
Elizabeth J CartwrightDivision of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester M13 9PT, United Kingdom.
Kairbaan Hodivala-DilkeBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure remains one of the largest clinical burdens globally, with little to no improvement in the development of disease-eradicating therapeutics. Integrin targeting has been used in the treatment of ocular disease and cancer, but little is known about its utility in the treatment of heart failure. Here we sought to determine whether the second generation orally available, αvβ3-specific RGD-mimetic,

Indexed as

Cardiac fibrosisCardiac hypertrophyHeart failureIntegrinRGD-mimeticTransverse aortic constriction

Identifiers

PMID38933087
PMCPMC11196926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.